Clinical Trial

Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Phase 2 clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in the pediatric population aged 2 months (minimum 42 days) to 5 years. The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, positive controlled phase 2 clinical trial.
Trial Details
NCT Number NCT07300644
Lead Sponsor Sinovac Life Sciences Co., Ltd.
Conditions Pneumococcal Infectious Disease
Enrollment 420 participants
Start Date 2025-11-25
Primary Completion 2026-09 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-24